Emerging investigations on retatruded, a dual agonist for incretin hormone and gastric inhibitory polypeptide, suggest promising outcomes in addressing excess body fat and type 2 diabetic condition. Initial data from clinical assessments point to considerable reductions in body bulk and bettered